

# 台灣癌症登記中心通知

**急件**

發件人： 台灣癌症登記中心  
電話： 02-2351-1708  
傳真： 02-2351-1733  
地址： 100 台北郵政 84-310 信箱  
日期： 113 年 12 月 20 日  
編號： 癌登第 113003 號

收文者： 所有申報醫院

副本收文者： 衛生福利部國民健康署、台灣癌症登記學會、資拓宏宇國際股份有限公司

主題： 癌症登記摘錄手冊發布，與因應癌症登記實務作業之需求，請貴院依說明段辦理

急件       請檢閱       請加註       請回覆       請回收

- 一、 本案係依衛生福利部國民健康署委託「台灣癌症登記工作計畫」辦理。
- 二、 自 **114 年第一季**起，所有癌症個案申報全面採用 113 年 12 月修訂之 107 年 v.7「台灣癌症登記長表/短表摘錄手冊」、「癌症部位特定因子編碼手冊」規則申報。請至癌症登記中心網站下載 [https://twcr.tw/?page\\_id=1809](https://twcr.tw/?page_id=1809)。
- 三、 107 年版台灣癌症登記摘錄手冊-113 年修訂版，主要修改內容如下：
  - (1) 「最初診斷日期」新增特定癌別之影像報告和數據系統 (Imaging Reporting and Data System, RADS) 分類結果符合可申報條件，且後續經顯微鏡證實為癌症或醫師有臨床判斷並支持此檢查報告時，該影像檢查日期可視為最初診斷日期。
  - (2) 「腫瘤大小」修改一般編碼指引順序與編碼定義。
  - (3) 「臨床分期字根/字首」、「病理分期字根/字首」編碼 3 定義 (同一原發部位有多顆腫瘤) 不適用於原位癌個案。
  - (4) 「其他分期系統」、「其他分期系統期別(臨床)」、「其他分期系統期別(病理)」欄位，新增收錄 0-17 歲兒童癌症個案癌症分期資訊，鼓勵醫學中心或準醫學中心試行申報。
  - (5) 「原發部位手術切緣距離」新增編碼 A01-A09。
  - (6) 「申報醫院化學治療」新增編碼指引：個案若因基因檢測結果而未執行既定的化學治療，則編碼 81。

- (7) 乳癌 SSF7 「HER2 免疫組織化學法的實驗數值」修改編碼指引與 500-502 定義，並新增編碼 530-532。
- (8) 子宮體癌新增 SSF4「POLE 基因突變」、SSF5「微星體不穩定檢測」與 SSF6「p53 基因突變」。

#### 四、自 114 診斷年起，癌症登記申報重要通知：

- (1) 將依據世界衛生組織於 2025 年出版國際疾病分類-腫瘤學第四版 (ICD-O-4)規則編碼，癌症組織型態代碼長度由原 4 碼擴增為 5 碼，並於 115 年起正式申報。
- (2) 0-17 歲兒童癌症個案癌症分期收錄，正式申報。醫學中心或準醫學中心，兒癌分期資訊為必填；其餘長表醫院鼓勵申報；若醫學中心非全癌症採用長表申報格式，兒癌個案應依長表格式進行申報。
- (3) 考量癌症家族史為多種癌症重要影響因子，癌症登記申報將新增收錄「同癌家族病史」欄位，並調整欄位數為長表 116 欄位與短表 46 欄位。
- (4) 因應癌症登記實務與國內外診療資訊需求日增，為配合前述癌症登記申報規則之調整，針對癌症登記申報項目進行欄位擴增，且同步更新「癌症登記線上申報系統 2.0」，請醫院預做準備，以利於 115 年改版申報作業順利推行。

#### 五、為配合癌症登記申報需求，建議貴院於病歷中詳實記錄「兒童癌症期別」與「癌症家族病史」相關資訊，並於內部宣導，以共同提升我國癌症登記資料之完整性與正確性。

前述四、五點，國民健康署近期將發文通知各醫院，請多加留意。

#### 六、依據 2024 年出版 WHO Classification of Tumours 第 5 版 Head and Neck Tumours 與 Haematolymphoid Tumours，統整最新病理組織形態代碼申報原則（附件一），適用於 2024 診斷年起個案。請注意有關口咽鱗狀細胞癌 HPV p16 編碼原則：

- 因 HPV p16 檢測結果比特定組織形態（例如：Keratinizing squamous cell carcinoma、Basaloid squamous cell carcinoma 等）更為重要
- 若 HPV p16 檢測結果為陽性，即使確診為特定組織形態，應優先以 **8085/3** 編碼

- 若 HPV p16 檢測結果為陰性，即使確診為特定組織形態，應優先以 **8086/3** 編碼
  - 若 HPV p16 未檢測或無法得知其結果時，則可依特定組織形態編碼。  
例如：Keratinizing squamous cell carcinoma 編碼為 8071/3、Basaloid squamous cell carcinoma 編碼為 8083/3...等。
- 七、近年依據 WHO Classification of Tumours 第 5 版彙整最新病理組織形態編碼，所有新增修訂處請詳見附件二彙整表。
- 八、為提升國家癌症登記年報完成時效，請依癌症防治法規定於 **113 年 12 月 31 日** 法定截止日期前，完成長表/短表申報作業。另為配合國健署年報記者會公告時程提前，將於 **114 年 2 月底** 開始進行「112 診斷年院際複查」作業，相關內容將另行通知，請各醫院協助優先回覆複查作業。
- 九、再次提醒，113 年度需完成五年追蹤之個案為 **108(含)年前診斷** 之個案，請務必於 **114 年 2 月 28 日前** 完成癌症個案五年追蹤資料申報，以免影響當年度之經費核銷計算與 114 年追蹤率成績。
- 十、最新 AJCC Version 9 於 2024 年 12 月出版四本 Thymus / Lung / Diffuse Pleural Mesothelioma / Nasopharynx Cancer Staging System，適用於 114 年 1 月 1 日起新診斷之個案，相關之 TNM 與 stage 編碼對應表，預計二月底前發文通知各醫院，請多加留意。有關書籍資訊可參考下列網址：  
<https://www.amazon.com/Version-9-of-the-AJCC-Cancer-Staging-System-4-book-series/dp/B091S5NMYB>

附件一. 摘錄適用於 2024 診斷年以後個案之新增修訂處

Status	ICD-O-3	Term
New term	8044/3	Small cell carcinoma, <b>hypercalcaemic type (C56.9)</b> Small cell carcinoma, <b>large cell variant (C56.9)</b> <b>Thoracic SMARCA4-deficient undifferentiated tumour (C34._)</b> <b>SMARCB1-deficient sinonasal carcinoma (C30._, C31._)</b> <b>SMARCB1-deficient sinonasal adenocarcinoma (C30._, C31._)</b> <b>SMARCA4-deficient sinonasal carcinoma (C30._, C31._)</b>
New term	8072/3	<b>DEK::AFF2</b> squamous cell carcinoma (C30._, C31._)
New code and term	<b>8085/2</b>	<b>HPV-associated oral epithelial dysplasia, high grade (C02._, C03._, C04._, C05._, C06._)</b>
New code and term	<b>8085/3</b>	<b>Squamous cell carcinoma, HPV-positive (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._)</b> <b>Squamous cell carcinoma, HPV-associated (C51._, C52.9, C53._, C60._, C63.2)</b> <b>Squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Non-keratinizing squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Keratinizing squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Papillary squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Adenosquamous carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Ciliated adenosquamous carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Lymphoepithelial carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>spindle cell / sarcomatoid squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Basaloid squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b>
New code and term	<b>8086/3</b>	<b>Squamous cell carcinoma, HPV-negative (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._)</b> <b>Squamous cell carcinoma, HPV-independent (C51._, C52.9, C53._)</b> <b>Squamous cell carcinoma, usual type (C60._, C63.2) [HPV-independent]</b> <b>Squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Keratinizing squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Verrucous carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Papillary squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Adenosquamous carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Lymphoepithelial carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>spindle cell / sarcomatoid squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Basaloid squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b>
New term	8140/3	<b>Endolymphatic sac tumor (C30.1)</b> <b>Parathyroid carcinoma (C75.0)</b> <b>Carcinoma of Skene, Cowper and Littre glands (C52.9, C68.0)</b> <b>Acinar adenocarcinoma of prostate (C61.9)</b> <b>Pleomorphic giant cell acinar adenocarcinoma (C61.9)</b> <b>Prostatic intraepithelial neoplasia-like carcinoma (C61.9)</b> <b>Renal cell-like sinonasal adenocarcinoma (C30._, C31._)</b>

Status	ICD-O-3	Term
New term	8240/3	Neuroendocrine tumor, <b>NOS</b> (C51._, C57.9) <b>Middle ear neuroendocrine tumour</b> (C30.1)
New term	8260/3	<b>Low-grade</b> papillary adenocarcinoma (C37.9) <b>Low-grade nasopharyngeal papillary adenocarcinoma</b> (C11._) <b>Middle ear adenocarcinoma</b> (C30.1)
New code and term	<b>8483/3</b>	<b>Adenocarcinoma, HPV-associated</b> (C52.9, C53._) <b>HPV-related multiphenotypic sinonasal carcinoma</b> (C30._, C31._)
New term	8502/3	Secretory carcinoma (C07._, C08._, C50._, C69.5) <b>Microsecretory adenocarcinoma</b> (C07._, C08._)
New term	8525/3	Polymorphous adenocarcinoma, <b>conventional subtype</b> (C07._, C08._) Polymorphous adenocarcinoma, <b>cribriform subtype</b> (C07._, C08._) <b>Cribriform adenocarcinoma of the salivary glands</b> (C07._, C08._)
New term	8900/3	Rhabdomyosarcoma <b>with TFCP2 rearrangement</b> (C47._, C49._)
New term	8940/3	<b>Metastasizing pleomorphic adenoma</b> (C07._, C08._)
New code and term	<b>9150/3</b>	<b>GLI1-altered soft tissue tumour</b> (C01._, C02._, C03._, C04._, C05._, C06._, C09._, C10._)
New term	9184/3	<b>Secondary osteosarcoma</b> (C40._, C41._) <b>Radiation-induced osteosarcoma</b> (C41.0)
New term	9220/3	Chondrosarcoma, <b>grade 2/3</b> (C12.9, C13._, C14._, C32._, C33.9, C41.0, C41.1, C40._, C41._)
<b>New code and term</b>	<b>9222/1</b>	<b>Chondrosarcoma, grade 1</b> (C12.9, C13._, C14._, C32._, C33.9)
New term	9270/3	<b>Sclerosing odontogenic carcinoma</b> (C41.0, C41.1) <b>Central intraosseous mucoepidermoid carcinoma</b> (C07._, C08._)
New behavior code and term	9363/3	Melanotic neuroectodermal tumor, <b>malignant</b> (C02._, C03._, C04._, C05._, C06._)
New term	9372/3	<b>Poorly differentiated chordoma</b> (C30._, C31._)
New term	9591/3	Splenic B-cell lymphoma/leukaemia with <b>prominent nucleoli</b>
New term	9596/3	<b>Mediastinal grey zone lymphoma</b>
New term	9650/3	<b>Classic Hodgkin lymphoma</b>
New term	9673/3	<b>Conventional mantle cell lymphoma</b> <b>Leukaemic non-nodal mantle cell lymphoma</b> <b>Cyclin D1-positive mantle cell lymphoma</b> <b>Cyclin D1-negative mantle cell lymphoma</b>

Status	ICD-O-3	Term
New term	9678/3	<b>Fibrin-associated large B-cell lymphoma</b> <b>Fluid overload-associated large B-cell lymphoma</b> <b>Extracavitary primary effusion lymphoma</b>
New term	9680/3	Diffuse large B-cell lymphoma (DLBCL), <b>Germinal centre B-cell subtype</b> Diffuse large B-cell lymphoma (DLBCL), <b>Activated B-cell subtype</b> <b>Fibrin-associated</b> diffuse large B-cell lymphoma <b>High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements</b> <b>High-grade B-cell lymphoma, NOS</b> <b>Vitreoretinal lymphoma (C69.2)</b> <b>Primary large B-cell lymphoma of immune-privileged sites</b> <b>Primary large B-cell lymphoma of the testis</b>
New term	9687/3	<b>High-grade B-cell Burkitt-like lymphoma with 11q aberration</b> <b>Acute leukaemia, Burkitt type</b> <b>Endemic Burkitt lymphoma</b> <b>Sporadic Burkitt lymphoma</b> <b>Immunodeficiency-associated Burkitt lymphoma</b> <b>EBV-associated Burkitt lymphoma</b> <b>EBV-negative Burkitt lymphoma</b>
New behavior code and term	9695/1	<b>In situ follicular neoplasia</b> <b>In situ follicular B-cell neoplasia</b>
New term	9698/3	<b>Large B-cell lymphoma with IRF4 rearrangement</b> <b>Follicular large B-cell lymphoma</b>
New term	9699/3	<b>Primary choroidal lymphoma (C69.3)</b> <b>Primary cutaneous marginal zone lymphoma</b> <b>Primary cutaneous marginal zone lymphoma, heavy chain class-switched form (IgG+, IgA+, or IgE+)</b> <b>Primary cutaneous marginal zone lymphoma, non-class-switched form (IgM+)</b> <b>Paediatric nodal marginal zone lymphoma</b>
New behavior code and term	9702/1	<b>Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract</b> <b>Indolent T-cell lymphoma of the gastrointestinal tract</b> <b>Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract</b>
New term	9702/3	<b>Follicular T-cell lymphoma</b> <b>Nodal peripheral T-cell lymphoma with T follicular helper phenotype</b> <b>Nodal T follicular helper cell lymphoma, follicular type</b> <b>Nodal T follicular helper cell lymphoma, NOS</b> <b>EBV-positive nodal T- and NK-cell lymphoma</b>
New term	9705/3	<b>Nodal T follicular helper cell lymphoma, angioimmunoblastic type (ICD-O-4 97028/3)</b>

Status	ICD-O-3	Term
New term	9709/3	Primary cutaneous <b>acral</b> CD8-positive T-cell lymphoma Primary cutaneous <b>acral</b> CD8 positive T-cell <b>lymphoproliferative disorder</b> Primary cutaneous <b>peripheral</b> T-cell lymphoma, NOS
Behavior code change (3→1)	9725/1	Hydroa vacciniforme-like lymphoproliferative disorder Classic hydroa vacciniforme lymphoproliferative disorder Systemic hydroa vacciniforme lymphoproliferative disorder <b>Systemic chronic active EBV-positive disease</b>
New behavior code and term	9727/1	<b>Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm</b>
New term	9732/3	<b>Smouldering (asymptomatic) myeloma</b> <b>Non-secretory myeloma</b>
New term	9738/3	<b>KSHV/HHV8-positive diffuse</b> large B-cell lymphoma
New term	9750/3	<b>Alk-positive</b> histiocytosis
New term	9758/3	<b>EBV-positive inflammatory</b> follicular dendritic cell sarcoma
New behavior code and term	9760/1	<b>IgG4-related disease</b>
New term	9761/3	<b>IgM-type lymphoplasmacytic lymphoma</b> / Waldenström macroglobulinaemia <b>Non-IgM-type lymphoplasmacytic lymphoma</b> / Waldenström macroglobulinaemia
New term	9762/3	Heavy chain <b>deposition</b> disease
New term	9805/3	Acute leukaemia of <b>ambiguous</b> lineage with <b>other defined genetic alterations</b> <b>Mixed-phenotype</b> acute leukaemia with <b>ZNF384 rearrangement</b> Acute leukaemia of <b>ambiguous</b> lineage with <b>BCL11B rearrangement</b> <b>Mixed-phenotype</b> acute leukaemia, <b>B/T (MPAL-B/T)</b> <b>Mixed-phenotype</b> acute leukaemia, <b>B/T/Myeloid (MPAL-B/T/M)</b> <b>Mixed-phenotype</b> acute leukaemia, <b>T/Megakaryocytic (MPAL-T/Mk)</b> Acute leukaemia of <b>ambiguous</b> lineage, <b>NOS</b>
New term	9811/3	B-lymphoblastic leukaemia/lymphoma <b>with iAMP21</b> B-ALL with <b>DUX4 rearrangement</b> B-ALL with <b>MEF2D rearrangement</b> B-ALL with <b>ZNF384 rearrangement</b> B-ALL with <b>PAX5 alteration</b> B-ALL with <b>PAX5 p.P80R variant</b> B-ALL with <b>NUTM1 rearrangement</b> <b>B-lymphoblastic Leukaemia/lymphoma with other defined genetic alterations</b> <b>B-ALL with MYC rearrangement</b>

Status	ICD-O-3	Term
New term	9816/3	B-ALL with <b>near-haploidy</b> B-ALL with <b>low hypodiploidy</b> B-ALL with <b>high hypodiploidy</b> B-ALL with hypodiploidy, <b>near-haploidy</b> B-ALL with hypodiploidy, <b>low hypodiploidy</b> B-ALL with hypodiploidy, <b>high hypodiploidy</b>
New term	9818/3	B-ALL with <b>TCF3::HLF fusion</b> B-lymphoblastic leukaemia/lymphoma with TCF3:: <b>PBX1 fusion</b>
New term	9827/3	<b>Smouldering</b> adult T-cell Leukaemia/lymphoma <b>Chronic</b> adult T-cell Leukaemia/lymphoma <b>Lymphoma</b> adult T-cell Leukaemia/lymphoma <b>Acute</b> adult T-cell Leukaemia/lymphoma
New term	9861/3	AML with <b>NUP98 rearrangement</b> AML with <b>MNX1::ETV6 fusion</b> AML with <b>KAT6A::CREBBP fusion</b> AML with <b>CBFA2T3::GLIS2 fusion</b> Acute myeloid leukaemia <b>with other defined genetic alterations</b> AML with <b>FUS::ERG fusion</b> AML with <b>NPM1::MLF1 fusion</b>
New term	9866/3	Acute promyelocytic leukaemia <b>with a variant RARA translocation</b>
New term	9876/3	<b>Myelodysplastic/myeloproliferative neoplasm with neutrophilia</b>
New code and term	<b>9878/3</b>	<b>AML with biallelic mutation of CEBPA</b> [originally 9861/3] <b>Acute myeloid leukaemia with CEBPA mutation</b> [originally 9861/3]
New term	9911/3	Acute myeloid leukaemia with RBM15:: <b>MRTFA fusion</b>
New term	9920/3	<b>Myeloid neoplasm post cytotoxic therapy</b> <b>Myelodysplastic/myeloproliferative neoplasm post cytotoxic therapy</b> Acute myeloid leukaemia <b>post cytotoxic therapy</b>
New term	9945/3	<b>Myelodysplastic</b> chronic myelomonocytic leukaemia ( <b>MD-CMML</b> ) <b>Myeloproliferative</b> chronic myelomonocytic leukaemia ( <b>MP-CMML</b> )
New code and term	<b>9968/3</b>	<b>Myeloid/lymphoid neoplasms with PCM1-JAK2</b> <b>Myeloid/lymphoid neoplasms with JAK2 rearrangement</b> <b>Myeloid/lymphoid neoplasm with FLT3 rearrangement</b> <b>Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion</b> <b>Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes</b>
New term	9980/3	<b>Myelodysplastic syndrome with single lineage dysplasia</b> <b>Myelodysplastic neoplasm with low blasts and single-lineage dysplasia</b>



Status	ICD-O-3	Term
New term	9982/3	<b>Myelodysplastic/myeloproliferative</b> neoplasm with ring siderolasts and thrombocytosis <b>Myelodysplastic syndrome</b> with ring sideroblasts and <b>single lineage dysplasia</b> <b>Myelodysplastic neoplasm with low blasts and SF3B1 mutation</b> <b>Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis</b>
New term	9983/3	<b>Myelodysplastic syndrome</b> with excess blasts <b>Myelodysplastic neoplasm with increased blasts/blasts-1/blasts-2/blasts and fibrosis</b> <b>Childhood myelodysplastic neoplasm with increased blasts</b>
New term	9985/3	<b>Myelodysplastic syndrome</b> with multilineage dysplasia <b>Myelodysplastic neoplasm with biallelic TP53 inactivation</b> <b>Myelodysplastic neoplasm with low blasts</b> <b>Myelodysplastic neoplasm with low blasts and multilineage dysplasia</b> <b>Myelodysplastic neoplasm, hypoplastic</b> <b>Childhood myelodysplastic neoplasm with low blast</b> <b>Childhood myelodysplastic neoplasm with low blast, hypocellular</b>
New term	9986/3	Myelodysplastic <b>neoplasm</b> with <b>low blasts</b> and 5q deletion

Status	ICD-O-3	Term
New term	8010/3	<b>Urachal</b> carcinoma (C65.9, C66.9, C67._, C68._)
New term	8013/3	<b>Combined</b> large cell neuroendocrine carcinoma (C57.9, C60-C68)
New term	8020/3	Carcinoma, <b>poorly differentiated</b> , NOS (C51._) Poorly differentiated urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Anaplastic thyroid</b> carcinoma (C73.9)
New code and term	<b>8023/3</b>	<b>NUT carcinoma (C30.0, C31._, C34._, C37.9)</b>
New term	8031/3	Giant cell <b>urothelial</b> carcinoma (C65.9, C66.9, C67._, C68._)
New term	8033/3	Carcinoma <b>with</b> sarcomatoid <b>component (C18._, C19.9, C20.9)</b>
New term	8035/3	<b>Squamous cell</b> carcinoma with osteoclast-like giant cells (C44._)
New term	8041/3	<b>High-grade</b> neuroendocrine carcinoma (C54._, C55.9)
New term	8041/3	Neuroendocrine carcinoma, <b>poorly differentiated</b> (C50._)
New term	8041/3	Small cell carcinoma, <b>pulmonary type (C56.9)</b>
New term	8044/3	Small cell carcinoma, <b>hypercalcaemic type (C56.9)</b> Small cell carcinoma, <b>large cell variant (C56.9)</b> <b>Thoracic SMARCA4-deficient undifferentiated tumour (C34._)</b> <b>SMARCB1-deficient sinonasal carcinoma (C30._, C31._)</b> <b>SMARCB1-deficient sinonasal adenocarcinoma (C30._, C31._)</b> <b>SMARCA4-deficient sinonasal carcinoma (C30._, C31._)</b>
New term	8045/3	Combined small cell <b>neuroendocrine</b> carcinoma (C57.9, C60-C68)
New term	8051/3	Verrucous carcinoma ( <b>including carcinoma cuniculatum</b> ) (C60._, C63.2)
New code and term	<b>8054/3</b>	<b>Warty carcinoma (C60._, C63.2)</b> [originally 8051/3]
New code and term	<b>8054/3</b>	<b>Condylomatous carcinoma (C60._, C63.2)</b> [originally 8051/3]
New term	8070/3	<b>Nasopharyngeal</b> carcinoma (C11._)
New behavior code and term	8071/2	<del>Differentiated-type</del> <b>vulvar intraepithelial neoplasia (C51._)</b> <b>Differentiated exophytic vulvar intraepithelial lesion (C51._)</b> <b>Vulvar acanthosis with altered differentiation (C51._)</b> <b>Differentiated penile intraepithelial neoplasia (C60._)</b> [HPV-independent]
New term	8071/3	<b>Keratoacanthoma</b> (C44._, C69.0)
New term	8072/3	<b>DEK::AFF2</b> squamous cell carcinoma (C30._, C31._)
New term	8074/3	<b>Pseudovascular</b> squamous cell carcinoma (C44._)

Status	ICD-O-3	Term
New term	8077/2	<b>Penile</b> intraepithelial neoplasia (C60._) High-grade squamous intraepithelial <b>lesion</b> (C60._) [ <b>HPV-associated</b> ]
New term	8077/2	Oral epithelial dysplasia, high grade (C00._, C02._, C03._, C04._, C05._, C06._)
New term	8082/3	Lymphoepithelioma-like <b>urothelial</b> carcinoma (C65.9, C66.9, C67._, C68._)
New code and term	<b>8085/2</b>	<b>HPV-associated oral epithelial dysplasia, high grade (C02._, C03._, C04._, C05._, C06._)</b>
New code and term	<b>8085/3</b>	<b>Squamous cell carcinoma, HPV-positive (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._)</b> <b>Squamous cell carcinoma, HPV-associated (C51._, C52.9, C53._, C60._, C63.2)</b> <b>Squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Non-keratinizing squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Keratinizing squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Papillary squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Adenosquamous carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Ciliated adenosquamous carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Lymphoepithelial carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>spindle cell / sarcomatoid squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Basaloid squamous cell carcinoma, HPV-associated (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b>
New code and term	<b>8086/3</b>	<b>Squamous cell carcinoma, HPV-negative (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._)</b> <b>Squamous cell carcinoma, HPV-independent (C51._, C52.9, C53._)</b> <b>Squamous cell carcinoma, usual type (C60._, C63.2) [HPV-independent]</b> <b>Squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Keratinizing squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Verrucous carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Papillary squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Adenosquamous carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Lymphoepithelial carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>spindle cell / sarcomatoid squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b> <b>Basaloid squamous cell carcinoma, HPV-independent (C01.9, C02.4, C05.1, C05.2, C09._, C10._)</b>
New term	8090/3	Basal cell carcinoma with <b>adnexal differentiation</b> (C44._)
New term	8091/3	Superficial basal cell carcinoma (C44._)
New term	8092/3	Basal cell carcinoma with <b>sarcomatoid differentiation</b> (C44._)
New term	8098/3	Adenoid basal carcinoma ( <b>C52.9</b> )
New behavior code and term	<b>8100/3</b>	<b>Trichoblastic carcinoma/carcinosarcoma</b> (C44._)

Status	ICD-O-3	Term
New term	8120/3	<p><b>Squamotransitional cell carcinoma (C53._)</b></p> <p><b>Conventional</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)</p> <p>Urothelial carcinoma <b>with squamous differentiation</b> (C65.9, C66.9, C67._, C68._)</p> <p>Urothelial carcinoma <b>with glandular differentiation</b> (C65.9, C66.9, C67._, C68._)</p> <p>Urothelial carcinoma <b>with trophoblastic differentiation</b> (C65.9, C66.9, C67._, C68._)</p> <p><b>Nested</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)</p> <p><b>Large nested</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)</p> <p><b>Tubular and microcystic</b> urothelial carcinomas (C65.9, C66.9, C67._, C68._)</p> <p><b>Lipid-rich</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)</p> <p><b>Clear cell (glycogen-rich)</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)</p> <p><b>Sarcomatoid</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) [原申報 8122/3]</p>
New term	8122/3	<b>Plasmacytoid</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)
New term	8130/2	<p>Non-invasive papillary urothelial carcinoma, <b>low grade</b> (C65.9, C66.9, C67._, C68._)</p> <p><b>Low-grade</b> papillary urothelial carcinoma <b>with an inverted growth pattern</b> (C65.9, C66.9, C67._, C68._)</p> <p>Non-invasive papillary urothelial carcinoma, <b>high grade</b> (C65.9, C66.9, C67._, C68._)</p> <p>Non-invasive <b>high-grade</b> papillary urothelial carcinoma <b>with an inverted growth pattern</b> (C65.9, C66.9, C67._, C68._)</p>
New term	8140/3	<p><b>Endolymphatic sac tumor (C30.1)</b></p> <p><b>Parathyroid carcinoma (C75.0)</b></p> <p><b>Carcinoma of Skene, Cowper and Littre glands (C52.9, C68.0)</b></p> <p><b>Acinar adenocarcinoma of prostate (C61.9)</b></p> <p><b>Pleomorphic giant cell acinar adenocarcinoma (C61.9)</b></p> <p><b>Prostatic intraepithelial neoplasia-like carcinoma (C61.9)</b></p> <p><b>Renal cell-like sinonasal adenocarcinoma (C30._, C31._)</b></p>
New behavior code and term	8144/2	<p><b>Intestinal-type adenoma, high grade (C16._, C17._, C24.1)</b></p> <p><b>Sporadic intestinal-type gastric adenoma (C16._)</b></p> <p><b>Syndromic intestinal-type gastric adenoma (C16._)</b></p>
New term	8144/3	<p>Enteric adenocarcinoma (C34._, C65.9, C66.9, C67._, C68._)</p> <p>Adenocarcinoma, intestinal type (<b>C51._</b>)</p> <p><b>Mucinous carcinoma, intestinal type (C53._)</b></p>
New term	8147/3	<b>Adenoid cystic (basal cell) carcinoma (C61.9)</b>
New term	8148/2	Prostatic intraepithelial neoplasia, <b>high-grade</b> (C61.9)

Status	ICD-O-3	Term
Behavior code change (0→3)	8150/3	Islet cell adenoma (C25._) Islet cell adenomatosis (C25._) Nesidioblastoma (C25._)
Behavior code change (1→3)	8150/3	Islet cell tumor, NOS (C25._) Pancreatic endocrine tumor, NOS (C25._)
New term	8150/3	<b>Oncocytic neuroendocrine tumor, non-functioning pancreatic</b> (C25._) <b>Pleomorphic neuroendocrine tumor, non-functioning pancreatic</b> (C25._) <b>Clear cell neuroendocrine tumor, non-functioning pancreatic</b> (C25._) <b>Cystic neuroendocrine tumor, non-functioning pancreatic</b> (C25._)
Behavior code change (0→3)	8151/3	Insulinoma (C25._) Beta cell adenoma (C25._)
Behavior code change (1→3)	8152/3	Glucagonoma (C25._) Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor (C25._) L-cell tumor (C18._, C19.9, C20.9, C25._) Glucagon-like peptide-producing tumor (C18._, C19.9, C20.9, C25._) PP/PYY producing tumor (C18._, C19.9, C20.9, C25._)
Behavior code change (1→3)	8153/3	Gastrinoma (C16._, C17._, C24.1, C25._) G cell tumor Gastrin cell tumor
New term	8154/3	Mixed ductal- <b>neuroendocrine</b> carcinomas (C25._)
New term	8154/3	Mixed acinar- <b>neuroendocrine</b> carcinomas (C25._)
New term	8154/3	Mixed <b>neuroendocrine non-neuroendocrine neoplasm (MiNEN)</b> (C15-C26, C60-C68)
Behavior code change (1→3)	8155/3	VIPoma (C25._)
Behavior code change (1→3)	8156/3	Somatostatinoma (C16._, C17._, C24.1, C25._) Somatostatin cell tumor
New behavior code and term	8158/3	ACTH-producing tumour with Cushing syndrome (C25._)
Behavior code change (1→3)	8158/3	ACTH-producing tumour (C25._) Endocrine tumor, functioning, NOS
New term	8160/3	Large duct intrahepatic cholangiocarcinoma (C22.1) Small duct intrahepatic cholangiocarcinoma (C22.1)
New term	8163/2	Intra-ampullary papillary-tubular neoplasm (C17._, C24.1)

Status	ICD-O-3	Term
New term	8174/3	Hepatocellular carcinoma, steatohepatitis (C22.0) Hepatocellular carcinoma, macrotrabecular massive (C22.0) Hepatocellular carcinoma, chromophobe (C22.0) Hepatocellular carcinoma, neutrophil-rich (C22.0) Hepatocellular carcinoma, lymphocyte-rich (C22.0)
New term	8200/3	<b>Thymic carcinoma</b> with adenoid cystic carcinoma-like features <b>(C37.9)</b>
New term	8200/3	<b>Classic</b> adenoid cystic carcinoma (C50._) <b>Solid-basaloid</b> adenoid cystic carcinoma (C50._) Adenoid cystic carcinoma with <b>high-grade transformation</b> (C50._)
New term	8210/2	Adenomatous polyp, <b>high-grade dysplasia</b> (C16._, C17._, C18._, C19.9, C20.9, C24.1)
New behavior code and term	8211/2	Tubular adenoma, <b>high grade</b> (C18._, C19.9, C20.9)
New behavior code and term	8213/2	Serrated <b>dysplasia, high grade</b> (C16._, C17._, C18._, C19.9, C20.9, C24.1) <b>Intestinal-type dysplasia</b> (C16._) <b>Foveolar-type (gastric-type) dysplasia</b> (C16._) <b>Gastric pit/crypt dysplasia</b> (C16._) <del>Hyperplastic polyp, microvesicular type (C18._, C19.9, C20.9)</del> <del>Hyperplastic polyp, goblet cell (C18._, C19.9, C20.9)</del>
New term	8240/3	Neuroendocrine tumor, <b>NOS</b> (C51._, C57.9) <b>Middle ear neuroendocrine tumour</b> (C30.1)
Behavior code change (1→3)	8241/3	Carcinoid tumor, argentaffin
New term	8241/3	Serotonin-producing <b>tumour with and without carcinoid syndrome</b> (C25._)
Behavior code change (1→3)	8242/3	Enterochromaffin-like cell carcinoid, NOS ECL cell carcinoid, NOS
New term	8243/3	Goblet cell <b>adenocarcinoma</b> (C18.1)
New term	8249/3	Neuroendocrine tumor, <b>grade 3</b> (C15-C26)
New behavior code and term	8250/2	<b>Adenocarcinoma in situ, non-mucinous</b> (C34._)
New term	8250/3	<b>Lepidic</b> adenocarcinoma (C34._)
New behavior code and term	8253/2	<b>Adenocarcinoma in situ, mucinous</b> (C34._)
New term	8253/3	<b>Invasive</b> mucinous <b>adenocarcinoma</b> (C34._)
New term	8254/3	Mixed <b>invasive</b> mucinous and non-mucinous <b>adenocarcinoma</b> (C34._)
New code and term	<b>8256/3</b>	<b>Minimally invasive adenocarcinoma, non-mucinous</b> (C34._)
New code and term	<b>8257/3</b>	<b>Minimally invasive adenocarcinoma, mucinous</b> (C34._)

Status	ICD-O-3	Term
New term	8260/3	<b>Low-grade</b> papillary adenocarcinoma (C37.9) <b>Low-grade nasopharyngeal</b> papillary adenocarcinoma (C11._) <b>Middle ear</b> adenocarcinoma (C30.1)
New term	8261/2	Villous adenoma, <b>high grade</b> (C18._, C19.9, C20.9)
New term	8262/3	<b>Adenoma-like</b> adenocarcinoma (C18._, C19.9, C20.9)
New term	8263/2	Tubulovillous adenoma, <b>high grade</b> (C18._, C19.9, C20.9)
New term	8263/3	<b>Endometrioid</b> adenocarcinoma, <b>villoglandular</b> (C54._, C55.9)
New term	8263/3	<b>Villoglandular</b> carcinoma (C53._)
New term	8265/3	Micropapillary adenocarcinoma (C18._, C19.9, C20.9, C34._)
New behavior code and term	8271/3	<b>Sparsely granulated lactotroph tumour</b> (C75.1) <b>Densely granulated lactotroph tumour</b> (C75.1)
New term	8272/3	Pituitary <b>adenoma</b> / pituitary <b>neuroendocrine tumor (PitNET)</b> (C75.1) <b>Densely granulated somatotroph tumour</b> (C75.1) <b>Sparsely granulated somatotroph tumour</b> (C75.1) <b>Thyrotroph tumour</b> (C75.1) <b>Mature PIT1-lineage tumour</b> (C75.1) <b>Immature PIT1-lineage tumour</b> (C75.1) <b>Densely granulated corticotroph tumour</b> (C75.1) <b>Sparsely granulated corticotroph tumour</b> (C75.1) <b>Crooke cell tumour</b> (C75.1) <b>Gonadotroph tumour</b> (C75.1) <b>Unclassified plurihormonal tumours</b> (C75.1) <b>Null cell tumour</b> (C75.1)
New code and term	<b>8273/3</b>	<b>Pituitary blastoma</b> (C75.1)
New term	8280/3	<b>Mammosomatotroph tumour</b> (C75.1) <b>Acidophil stem cell tumour</b> (C75.1)
New term	8310/3	Adenocarcinoma, <b>HPV-independent</b> , clear cell type (C53._) <b>Hyalinizing</b> clear cell carcinoma (C34._) Clear cell renal cell carcinoma (C64.9)

Status	ICD-O-3	Term
New code and term	8311/3	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated renal cell carcinoma (C64.9) MiT family translocation renal cell carcinomas (C64.9) Eosinophilic solid and cystic renal cell carcinomas (C64.9) TFE3-rearranged renal cell carcinomas (C64.9) TFEB-altered renal cell carcinomas (C64.9) ELOC (formerly TCEB1)-mutated renal cell carcinomas (C64.9) Fumarate hydratase-deficient renal cell carcinomas (C64.9) ALK-rearranged renal cell carcinomas (C64.9) Succinate dehydrogenase-deficient renal cell carcinoma (C64.9)
New term	8312/3	<del>Succinate dehydrogenase-deficient renal carcinoma (C64.9)</del> 改申報 8311/3
New term	8316/3	Acquired cystic disease-associated renal cell carcinoma (C64.9) Tubulocystic renal cell carcinoma (C64.9)
Behavior code change (3→1)	8323/1	Clear cell papillary renal cell carcinoma (C64.9) [MP/H 8255/3→8323/1] >> Clear cell papillary renal cell tumour (C64.9) [WHO Blue books 5 <sup>th</sup> - terminology change]
New term	8330/3	Follicular thyroid carcinoma (FTC), widely invasive (C73.9)
Behavior code change (3→1)	8335/1	Follicular carcinoma, encapsulated (C73.9)
New term	8337/3	Poorly differentiated thyroid carcinoma (C73.9)
New code and term	8339/3	Follicular thyroid carcinoma (FTC), encapsulated angioinvasive (C73.9)
New term	8342/3	Oncocytic variant of papillary thyroid carcinoma (PTC) (C73.9)
New term	8345/3	Medullary thyroid carcinoma (C73.9)
New code and term	8349/1	Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (C73.9) [nonreportable]
New behavior code and term	8380/2	Atypical hyperplasia / Endometrioid intraepithelial neoplasia (C54._) Atypical hyperplasia of the endometrium (C54._)
New term	8380/3	POLE-ultramutated endometrioid carcinoma (C54._) Mismatch repair-deficient endometrioid carcinoma (C54._) p53-mutant endometrioid carcinoma (C54._) No specific molecular profile (NSMP) endometrioid carcinoma (C54._)
New term	8390/3	Adnexal adenocarcinoma, NOS (C44._)
New term	8401/3	Apocrine carcinoma (C44._)
New term	8403/3	Malignant neoplasms arising from spiradenoma, cylindroma, or spiradenocylindroma (C44._)
New behavior code and term	8406/3	Syringocystadenocarcinoma papilliferum (C44._)



Status	ICD-O-3	Term
<b>Behavior code change (1→3)</b>	<b>8408/3</b>	<b>Aggressive digital papillary adenoma (C44._)</b>
New behavior code and term	8409/2	Porocarcinoma <b>in situ</b> (C44._)
New term	8430/3	<b>Sclerosing</b> mucoepidermoid carcinoma <b>with eosinophilia</b> (C73.9)
New behavior code and term	8441/2	Serous <b>tubal intraepithelial</b> carcinoma <b>(C57.0)</b>
New behavior code and term	8441/2	Serous <b>endometrial intraepithelial</b> carcinoma <b>(C54._)</b>
New term	8441/3	Serous cystadenocarcinoma, NOS <b>(C25._, C56.9)</b>
New term	8452/1	Solid pseudopapillary tumour <b>of ovary (C56.9)</b>
New term	8452/3	Solid pseudopapillary neoplasm of the pancreas (C25._) Solid pseudopapillary neoplasm with high-grade carcinoma (C25._)
New code and term	<b>8455/2</b>	<b>Intraductal oncocytic papillary neoplasm, NOS (C25._)</b>
New code and term	<b>8455/3</b>	<b>Intraductal oncocytic papillary neoplasm with associated invasive carcinoma (C25._)</b>
New behavior code and term	8460/2	Serous <b>borderline tumour</b> - micropapillary variant <b>(C56.9)</b>
New behavior code and term	8460/2	<b>Non-invasive low-grade</b> serous carcinoma <b>(C56.9)</b>
New term	8460/3	<b>Low-grade</b> serous carcinoma (C48._, C56.9, C57._)
New term	8461/3	<b>High-grade</b> serous carcinoma (C48._, C56.9, C57._)
New term	8470/3	Mucinous cystadenocarcinoma NOS (C50._)
New code and term	<b>8474/3</b>	<b>Seromucinous carcinoma (C56.9)</b>
<b>Behavior code change (1→2)</b>	8480/2	<b>Low-grade</b> appendiceal mucinous neoplasm ( <b>LAMN</b> ) (C18.1) <b>[Beginning with cases diagnosed 1/1/2022 forward, LAMN should be assigned a behavior code of /2]</b> <b>Note: Effective 1/1/2022, LAMN becomes reportable and is coded 8480/2, unless the pathologist indicates invasive behavior, which is coded 8480/3.</b>
New behavior code and term	8480/2	<b>High-grade</b> appendiceal mucinous neoplasm (C18.1) <b>Note: Effective 1/1/2022, HAMN can be either /2 or /3 depending on the pathologist statement of behavior.</b>
New term	8480/3	Mucinous <b>tubular and spindle cell</b> carcinoma (C64.9)
New term	8482/3	Mucinous carcinoma, <b>gastric type</b> (C52.9, C53._) Adenocarcinoma, <b>HPV-independent, gastric type</b> (C53._)
New code and term	<b>8483/2</b>	<b>Adenocarcinoma in situ, HPV-associated (C53._)</b>
New code and term	<b>8483/3</b>	<b>Adenocarcinoma, HPV-associated (C52.9, C53._)</b> <b>HPV-related multiphenotypic sinonasal carcinoma (C30._, C31._)</b>
New code and term	<b>8484/2</b>	<b>Adenocarcinoma in situ, HPV-independent (C53._)</b>
New code and term	<b>8484/3</b>	<b>Adenocarcinoma, HPV-independent, NOS (C53._)</b>

Status	ICD-O-3	Term
New term	8490/3	Signet ring cell/ <b>histiocytoid</b> carcinoma (C44._)
New term	8500/2	DCIS of <b>low nuclear grade</b> (C50._) DCIS of <b>intermediate nuclear grade</b> (C50._) DCIS of <b>high nuclear grade</b> (C50._)
New term	8500/3	<b>Adenocarcinoma of mammary gland type (C51._)</b> <b>Adenocarcinoma of anogenital mammary-like glands (C51._)</b>
New term	8502/3	Secretory carcinoma (C07._, C08._, C50._, C69.5) <b>Microsecretory adenocarcinoma (C07._, C08._)</b>
New term	8503/2	Intraductal tubulopapillary neoplasm (C25._)
New term	8504/2	<b>Encapsulated papillary carcinoma (C50._)</b>
<b>Behavior code change (3→2)</b>	<b>8504/2</b>	<b>Intracystic carcinoma, NOS</b> <b>Intracystic papillary adenocarcinoma</b>
New term	8504/3	<b>Encapsulated papillary carcinoma with invasion (C50._)</b>
New behavior code and term	8507/3	<b>Invasive</b> micropapillary carcinoma (C50._)
New code and term	<b>8509/2</b>	<b>Solid papillary carcinoma in situ (C50._)</b>
New code and term	<b>8509/3</b>	<b>Endocrine mucin-producing sweat gland carcinoma (C44._)</b> <b>Solid papillary carcinoma invasive (C50._)</b> <b>Tall cell carcinoma with reversed polarity (C50._)</b>
New term	8510/3	<b>Renal</b> medullary carcinoma (C64.9) <b>SMARCB1-deficient</b> medullary-like renal cell carcinoma (C64.9) <b>SMARCB1-deficient undifferentiated renal cell carcinoma, NOS (C64.9)</b> <b>SMARCB1-deficient dedifferentiated renal cell carcinomas of other specific subtypes (C64.9)</b> <b>SMARCB1-deficient renal medullary carcinoma (C64.9)</b>
New code and term	<b>8519/2</b>	<b>Pleomorphic lobular carcinoma in situ (C50._)</b>
New term	8520/2	<b>Florid</b> lobular carcinoma in situ (C50._)
New term	8525/3	Polymorphous adenocarcinoma, <b>conventional subtype</b> (C07._, C08._) Polymorphous adenocarcinoma, <b>cribriform subtype</b> (C07._, C08._) <b>Cribriform</b> adenocarcinoma of the salivary glands (C07._, C08._)
New term	8551/3	Acinar <b>adenocarcinoma</b> (C34._)

Status	ICD-O-3	Term
New term	8560/3	Squamoid <b>eccrine ductal</b> carcinoma (C44._)
New term	8570/3	<b>Endometrioid carcinoma</b> with squamous differentiation (C54._) <b>Low grade</b> adenosquamous carcinoma (C50._)
New term	8571/3	<b>Metaplastic carcinoma</b> with <b>chondroid</b> differentiation (C50._) <b>Metaplastic carcinoma</b> with osseous differentiation (C50._)
New term	8572/3	<b>Fibromatosis-like</b> metaplastic carcinoma (C50._) <b>Acinar</b> adenocarcinoma, <b>sarcomatoid</b> (C61.9)
New term	8576/3	<b>Paneth cell</b> carcinoma (C16._)
New term	8580/3	<b>Metaplastic</b> thymoma / <b>Sclerosing</b> thymoma (C37.9)
New term	8580/3	<b>Ectopic</b> thymoma (C73.9)
<b>Behavior code change (1→3)</b>	<b>8581/3</b>	<b>Type A thymoma, including atypical variant (C37.9)</b>
<b>Behavior code change (1→3)</b>	<b>8582/3</b>	<b>Type AB thymoma (C37.9)</b>
<b>Behavior code change (1→3)</b>	<b>8583/3</b>	<b>Type B1 thymoma (C37.9)</b>
<b>Behavior code change (1→3)</b>	<b>8584/3</b>	<b>Type B2 thymoma (C37.9)</b>
<b>Behavior code change (1→3)</b>	<b>8585/3</b>	<b>Type B3 thymoma (C37.9)</b>
New term	8589/3	<b>Intrathyroid thymic</b> carcinoma (C73.9)
New code and term	<b>8594/1</b>	<b>Mixed germ cell-sex cord-stromal tumor, NOS (C56.9)</b>
<b>Behavior code change (1→3)</b>	<b>8620/3</b>	<b>Adult</b> granulosa cell tumor of <b>ovary</b> (C56.9)
New term	8620/1	<b>Adult</b> granulosa cell tumor of <b>testis (C62._)</b>
Behavior code change (1→3)	8680/3	Paraganglioma, NOS (C75.5)
Behavior code change (1→3)	8681/3	Sympathetic paraganglioma
Behavior code change (1→3)	8682/3	Parasympathetic paraganglioma
Behavior code change (1→3)	8690/3	Middle ear paraganglioma (C75.5) Glomus jugulare tumor, NOS (C75.5) Jugular paraganglioma (C75.5) Jugulotympanic paraganglioma (C75.5)
Behavior code change (1→3)	8691/3	Aortic body tumor (C75.5) Aortic body paraganglioma (C75.5) Aorticopulmonary paraganglioma (C75.5)
Behavior code change (1→3)	8692/3	Carotid body paraganglioma (C75.4) Carotid body tumor (C75.4)

Status	ICD-O-3	Term
Behavior code change (1→3)	8693/3	Extra-adrenal paraganglioma, NOS (C17._, C24.1, C60-C68) Nonchromaffin paraganglioma, NOS Chemodectoma
New term	8693/3	Vagal paraganglioma (C75.5) Laryngeal paraganglioma (C75.5) Sympathetic paragangliomas (C75.5) <b>Composite</b> paraganglioma (C75.5) Paraganglioma (C73.9, C75.1) <b>Cauda equina neuroendocrine tumour</b> (previously paraganglioma) (C72._) <b>Extra-adrenal composite paraganglion tumours</b> (C75._) <b>Composite</b> paraganglioma-neuroblastoma (C75._) <b>Composite</b> paraganglioma-ganglioneuroblastoma (C75._)
Behavior code change (0→3)	8700/3	Pheochromocytoma (C74.1) Adrenal medullary paraganglioma (C74.1) Chromaffin paraganglioma Chromaffin tumor Chromaffinoma
New term	8700/3	<b>Composite</b> pheochromocytoma (C74.1) <b>Composite paraganglion tumours</b> (C74.1) <b>Composite</b> pheochromocytoma-ganglioneuroma (C74.1) <b>Composite</b> pheochromocytoma-ganglioneuroblastoma (C74.1) <b>Composite</b> pheochromocytoma-neuroblastoma (C74.1) <b>Composite</b> pheochromocytoma-peripheral nerve sheath tumours (C74.1)
New code and term	<b>8714/3</b>	<b>Neoplasms with perivascular epithelioid cell differentiation (PEComa) NOS, malignant (C15-C26, C34._, C47._, C49._, <del>C54._,</del> C60-C68)</b> <b>Perivascular epithelioid cell tumour, malignant (C65.9, C66.9, C67._, C68._)</b> <b>Perivascular epithelioid tumour, malignant (C47._, C49._, C54._)</b>
New term	8720/3	<b>Mucosal</b> melanoma (genital, oral, sinonasal)
New term	8721/3	<b>Mucosal</b> nodular melanoma (genital, oral, sinonasal)
New term	8743/3	<b>Low-CSD (cumulative sun damage)</b> melanoma (C44._)
New term	8744/3	Acral melanoma (C44._)
New term	8770/3	<b>Malignant Spitz tumor (Spitz melanoma)</b> (C44._)
New term	8780/3	<b>Melanoma</b> arising in blue nevus (C44._)

Status	ICD-O-3	Term
New term	8801/3	<b>Undifferentiated</b> spindle cell sarcoma (C47._, C49._)
New term	8802/3	<b>Undifferentiated</b> pleomorphic sarcoma (C47._, C49._) Pleomorphic <b>dermal</b> sarcoma (C44._) <b>Anaplastic sarcoma of the kidney (C64.9)</b>
New term	8803/3	<b>Undifferentiated</b> round cell sarcoma (C47._, C49._)
New term	8804/3	<b>Undifferentiated</b> epithelioid sarcoma (C47._, C49._) <b>Proximal or large cell</b> epithelioid sarcoma (C47._, C49._) <b>Classic</b> epithelioid sarcoma (C47._, C49._)
New term	8811/3	Myxofibrosarcoma (C47._, C49._) <b>Epithelioid</b> myxofibrosarcoma (C47._, C49._)
New behavior code and term	8825/3	<b>Low-grade</b> myofibroblastic sarcoma (C47._, C49._) Myofibroblastic <b>sarcoma</b> (C47._, C49._) <b>Epithelioid inflammatory myofibroblastic sarcoma (C15-C26)</b>
New term	8830/3	Undifferentiated high-grade pleomorphic sarcoma of <b>bone</b> (C40._, C41._)
<b>Behavior code change (3→1)</b> (revised)	<b>8832/1</b>	<b>Dermatofibrosarcoma protuberans (C47._, C49._)</b> <b>Myxoid</b> dermatofibrosarcoma protuberans (C47._, C49._) Dermatofibrosarcoma protuberans <b>with myoid differentiation</b> (C47._, C49._) <b>Plaque-like</b> dermatofibrosarcoma protuberans (C47._, C49._)
New term (revised)	8832/3	<b>Fibrosarcomatous</b> dermatofibrosarcoma protuberans (C47._, C49._) <del><b>Myxoid</b> dermatofibrosarcoma protuberans (C47._, C49._)</del> <del>Dermatofibrosarcoma protuberans <b>with myoid differentiation</b> (C47._, C49._)</del> <del><b>Plaque-like</b> dermatofibrosarcoma protuberans (C47._, C49._)</del>
<b>Behavior code change (3→1)</b>	<b>8833/1</b>	<b>Pigmented dermatofibrosarcoma protuberans (C44._, C47._, C49._)</b> <b>Bednar tumor (C44._)</b>
New term	8840/3	<b>Low-grade fibromyxoid sarcoma (C47._, C49._)</b> <b>Sclerosing epithelioid fibrosarcoma (C47._, C49._)</b>
New behavior code and term	8842/3	<b>Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation fusion (C34._)</b> <b>Ossifying fibromyxoid tumour, malignant (C47._, C49._)</b>
New term	8854/3	<b>Epithelioid</b> liposarcoma (C47._, C49._)
New code and term	<b>8859/3</b>	<b>Myxoid pleomorphic liposarcoma (C47._, C49._)</b>
New term	8890/3	<b>Spindle</b> leiomyosarcoma (C54._) <b>Superficial</b> leiomyosarcoma (C60-C68) <b>Deep</b> leiomyosarcoma (C60-C68)

Status	ICD-O-3	Term
New term	8900/3	Rhabdomyosarcoma <b>with TFCP2 rearrangement</b> (C47._, C49._)
New term	8912/3	Sclerosing rhabdomyosarcoma <b>Congenital</b> spindle cell rhabdomyosarcoma <b>with VGLL2/NCOA2/CITED2 rearrangements</b> (C47._, C49._) <b>MYOD1-mutant</b> spindle cell / sclerosing rhabdomyosarcoma (C47._, C49._) <b>Intraosseous</b> spindle cell rhabdomyosarcoma ( <b>with TFCP2/NCOA2 rearrangements</b> ) (C47._, C49._)
New term	8930/3	Endometrioid stromal sarcoma, high grade (C48._, C56.9)
New term	8931/3	Endometrioid stromal sarcoma, low grade (C48._, C56.9)
New term	8936/3	<b>Extra-gastrointestinal stromal tumour</b> (C48._) <b>Succinate dehydrogenase-deficient</b> gastrointestinal stromal tumour (C47._, C49._)
New term	8940/3	<b>Metastasizing pleomorphic adenoma</b> (C07._, C08._)
New term	8960/3	Wilms tumour (C56.9)
New term	8963/3	<b>Extra-renal rhabdoid tumour</b> (C47._, C49._, C60-C68)
New code and term <b>Behavior code change (1→3)</b>	<b>8976/3</b>	<b>Gastroblastoma</b> (C16._) [Beginning with cases diagnosed 1/1/2022 forward, Gastroblastoma should be assigned a behavior code of /3]
New behavior code and term	8983/3	Adenomyoepithelioma <b>with carcinoma</b> (C50._)
New term	8990/3	<b>Phosphaturic</b> mesenchymal tumor, malignant <b>NTRK-rearranged spindle cell neoplasm (emerging)</b>
New term	9020/3	<b>Periductal stromal tumor, low grade</b> (C50._)
New term	9044/3	<b>Dermal</b> clear cell sarcoma (C44._)
New code and term	<b>9045/3</b>	<b>Biphenotypic sinonasal sarcoma</b> (C30.0, C31._)
New behavior code and term	9050/2	Mesothelioma <b>in situ</b> (C38.4)
New term	9050/3	<b>Localized</b> mesothelioma (C38.4) <b>Diffuse</b> mesothelioma, NOS (C38.4)
New behavior code and term	9061/2	<b>Intratubular</b> seminoma (C62._) <b>Intratubular trophoblast</b> (C62._)
New term	9061/3	Seminoma <b>with syncytiotrophoblastic cells</b> (C62._)
New behavior code and term	9070/2	<b>Intratubular</b> embryonal carcinoma (C62._)
New behavior code and term	9071/2	<b>Intratubular</b> yolk sac tumour (C62._)
New term	9071/3	Yolk sac tumor, <b>pre-pubertal type</b> (C52.9, C62._) Yolk sac tumor, <b>postpubertal-type</b> (C62._)

Status	ICD-O-3	Term
Behavior code not change	9080/3	Immature teratoma, NOS <b>(C56.9)</b>
Behavior code change (3→1)	9080/1	Immature teratoma (C34._) Immature teratoma (C37.9) Immature teratoma <b>(grade 2) (C73.9)</b>
New behavior code and term	9080/2	<b>Intratubular</b> teratoma (C62._)
New term	9080/3	Teratoma, <b>postpubertal-type</b> (C62._)
New term	9081/3	Teratocarcinosarcoma (C30.0, C31._)
New term	9084/0	<b>Teratoma, prepubertal-type (C62._)</b>
New term	9084/3	<b>Germ cell tumours with sometic-type solid malignancy (C37.9)</b> Teratoma <b>with carcinoid (neuroendocrine tumour) (C64.9)</b> Teratoma with somatic-type malignancy (C62._) <b>Well differentiated neuroendocrine tumor (monodermal teratoma) (C62._)</b>
New term	9085/3	Mixed teratoma- <b>yolk sac tumor</b> (C64.9) <b>Polyembryoma (C62._)</b> <b>Diffuse embryoma (C62._)</b> Mixed teratoma and yolk sac tumour, <b>prepubertal-type (C62._)</b>
New code and term	<b>9086/3</b>	<b>Germ cell tumours with associated haematological malignancy (C37.9)</b>
New behavior code and term	9104/3	Placental site trophoblastic tumour <b>of the testis (C62._)</b>
New term	9110/3	Adenocarcinoma of <b>rete ovarii (C56.9)</b> Adenocarcinoma, <b>HPV-independent</b> , mesonephric type (C53._)
New code and term	<b>9111/3</b>	<b>Mesonephric-like adenocarcinoma (C54._, C56.9)</b>
New term	9120/3	<b>Postradiation</b> angiosarcoma (C50._) <b>Epithelioid</b> angiosarcoma (C50._, C60-C68)
Behavior code change (1→3)	9133/3	Epithelioid hemangioendothelioma (C30.0, C31._, C44._, C40._, C41._, C47._, C49._)
New term	9133/3	Epithelioid hemangioendothelioma <b>with WWTR1-CAMTA1 fusion</b> (C47._, C49._) Epithelioid hemangioendothelioma <b>with YAP1-TFE3 fusion</b> (C47._, C49._)
New code and term	<b>9137/3</b>	<b>Pulmonary artery intimal sarcoma (C34._)</b> <b>Intimal sarcoma (C34._, C47._, C49._)</b>
New code and term	<b>9150/3</b>	<b>GLI1-altered soft tissue tumour (C01._,C02._, C03._, C04._, C05._, C06._, C09._, C10._)</b>
New term	9170/3	<b>Diffuse lymphangiomatosis (C34._)</b>

Status	ICD-O-3	Term
New behavior code and term	9174/3	Lymphangiomyomatosis (C34._)
New term	9180/3	<b>Extraskeletal</b> osteosarcoma (C47._, C49._)
New term	9184/3	<b>Secondary</b> osteosarcoma (C40._, C41._) <b>Radiation-induced</b> osteosarcoma (C41.0)
New term	9187/3	Low-grade <b>central / intramedullary</b> osteosarcoma (C40._, C41._)
New term	9220/3	Chondrosarcoma, <b>grade 2/3</b> (C12.9, C13._, C14._, C32._, C33.9, C41.0, C41.1, C40._, C41._)
<b>New code and term</b>	<b>9222/1</b>	<b>Chondrosarcoma, grade 1</b> (C12.9, C13._, C14._, C32._, C33.9)
New code and term	<b>9222/3</b>	<b>Chondrosarcoma, grade 1</b> (C40._, C41._)
New term	9231/3	<b>Extraskeletal</b> myxoid chondrosarcoma (C47._, C49._)
New behavior code and term	9261/1	<b>Osteofibrous dysplasia-like</b> adamantinoma (C41.0, C41.1)
New term	9261/3	<b>Classic</b> adamantinoma ( <b>malignant</b> ) (C41.0, C41.1) <b>Dedifferentiated</b> adamantinoma (C41.0, C41.1)
New term	9270/3	<b>Sclerosing</b> odontogenic carcinoma (C41.0, C41.1) <b>Central intraosseous mucoepidermoid</b> carcinoma (C07._, C08._)
New behavior code and term	9302/3	Ghost cell odontogenic <b>carcinoma</b> (C41.0, C41.1)
New term	9330/3	<b>Odontogenic sarcomas</b> (C41.0, C41.1)
Behavior code change (1→3)	9341/3	Clear cell odontogenic tumor (C41.0, C41.1)
New behavior code and term	9341/3	Clear cell odontogenic <b>carcinoma</b> (C41.0, C41.1)
New term	9362/3	Pineoblastoma, <b>miRNA processing-altered_1</b> (C75.3) Pineoblastoma, <b>miRNA processing-altered_2</b> (C75.3) Pineoblastoma, <b>RB1-altered (pineal retinoblastoma)</b> (C75.3) Pineoblastoma, <b>MYC/FOXR2-activated</b> (C75.3)
New behavior code and term	9363/3	Melanotic neuroectodermal tumor, <b>malignant</b> (C02._, C03._, C04._, C05._, C06._)
New code and term	9366/3	<b>Round cell sarcoma with EWSR1-non-ETS fusions</b> (C40._, C41._, C47._, C49._) <b>Round cell sarcoma with EWSR1/FUS::NFATC2</b> (C40._, C41._, C47._, C49._) <b>Round cell sarcoma with EWSR1::PATZ1</b> (C40._, C41._, C47._, C49._)
New code and term	9367/3	<b>CIC-rearranged sarcoma</b> (C40._, C41._, C47._, C49._)
New code and term	9368/3	<b>Sarcoma with BCOR genetic alterations</b> (C40._, C41._, C47._, C49._)
New term	9370/3	<b>Poorly differentiated</b> chordoma (C40._, C41._) <b>Conventional</b> chordoma (C40._, C41._)
New term	9372/3	<b>Poorly differentiated</b> chordoma (C30._, C31._)



Status	ICD-O-3	Term
New code and term (revised)	9385/3	<del>Diffuse midline glioma, H3 K27-altered M-mutant / H3.3 K27-mutant / H3.1 or H3.2 K27-mutant / H3-wildtype with EZHIP overexpression / EGFR-mutant (C71.)</del> Diffuse hemispheric glioma, H3 G34-mutant (C71.) Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype / RTK2 / RTK1 / MYCN (C71.) Infant-type hemispheric glioma / NTRK-altered / ROS1-altered / ALK-altered / MET-altered (C71.)
New behavior code and term	9391/1	Sellar ependymoma (C75.1) [nonreportable]
New term	9391/3	Ependymoma, NOS (C57.) Supratentorial ependymoma, NOS (C71.) Posterior fossa ependymoma, NOS (C71.) Spinal ependymoma, NOS (C71., C72.0)
New code and term	9396/3	Ependymoma, RELA fusion-positive (C71.) Supratentorial ependymoma, ZFTA fusion-positive / YAP1 fusion-positive (C71.) Posterior fossa group A (PFA) / group B (PFB) ependymoma (C71.) Spinal ependymoma, MYCN-amplified (C71., C72.0)
New term (revised)	9400/3	Diffuse astrocytoma, <del>IDH-mutant, grade 2 / IDH-wildtype</del> (C71.)
New term (revised)	9401/3	Anaplastic astrocytoma, <del>IDH-mutant, grade 3 / IDH-wildtype</del> (C71.)
New term	9421/1	Diffuse astrocytoma, MYB- or MYBL1-altered (C71.) Diffuse low-grade glioma, MAPK pathway-altered (C71.) Diffuse low-grade glioma, FGFR1 tyrosine kinase domain-duplicated (C71.) Diffuse low-grade glioma, FGFR1-mutant (C71.) Diffuse low-grade glioma, BRAF p.V600E-mutant (C71.) Pilocytic astrocytoma with histological features of anaplasia
New behavior code and term	9421/3	High-grade astrocytoma with piloid features (C71.)
New term	9424/3	Anaplastic pleomorphic xanthoastrocytoma (C71.)
New term	9430/3	Astroblastoma, MN1-altered (C71.)
New term	9440/3	Epithelioid glioblastoma (C71.)
New term	9440/3	Glioblastoma, IDH-wildtype (C71.)
New code and term	9445/3	Glioblastoma, IDH-mutant (C71.) Astrocytoma, IDH-mutant, grade 4 (C71.)
New term (revised)	9450/3	Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 2 (C71.)
New term (revised)	9451/3	Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 (C71.)

Status	ICD-O-3	Term
New term	9470/3	Medulloblastoma, <b>classic</b> (C71._) Medulloblastoma, <b>histologically defined</b> (C71._)
New term	9471/3	Medulloblastoma, <b>SHH-activated and TP53-wildtype</b> (C71._)
New term (revised)	9473/3	<b>CNS embryonal tumour, NEC/NOS</b> (C71._)
New code and term	<b>9475/3</b>	<b>Medulloblastoma, WNT-activated</b> (C71._)
New code and term	<b>9476/3</b>	<b>Medulloblastoma, SHH-activated and TP53-mutant</b> (C71._)
New code and term	<b>9477/3</b>	<b>Medulloblastoma, non-WNT/non-SHH</b> (C71._) <b>Medulloblastoma, group 3 / group 4</b> (C71._)
New code and term	<b>9478/3</b>	<b>Embryonal tumour with multilayered rosettes, C19MC-altered</b> (C71._) <b>Embryonal tumour with multilayered rosettes, NOS</b> (C71._) <b>Embryonal tumour with multilayered rosettes, DICER1-mutant</b> (C71._)
New term	9480/3	<b>Primary intracranial sarcoma, DICER1-mutant</b> (C71._)
New term	9490/3	Ganglioneuroblastoma, <b>nodular</b> (C74.1) Ganglioneuroblastoma, <b>intermixed</b> (C74.1)
New term	9500/3	<b>CNS neuroblastoma, FOXR2-activated</b> (C71._) <b>CNS tumour with BCOR internal tandem duplication</b> (C71._)
New term	9508/3	<b>CNS embryonal tumour with rhabdoid features</b> (C71._)
New behavior code and term	9509/3	<b>Diffuse leptomenigeal</b> glioneuronal tumor (C71._) Diffuse leptomenigeal glioneuronal tumor <b>with 1q gain</b> (C71._) Diffuse leptomenigeal glioneuronal tumor, <b>methylation class 1 (DLGNT-MC-1)</b> (C71._) Diffuse leptomenigeal glioneuronal tumor, <b>methylation class 2 (DLGNT-MC-2)</b> (C71._)
New term	9540/3	<b>MPNST with perineurial differentiation</b> (C72._)
New code and term	<b>9542/3</b>	<b>Epithelioid malignant peripheral nerve sheath tumour</b> (C44._, C47._, C49._)
New behavior code and term	9591/1	<b>Monoclonal B-cell lymphocytosis, non-CLL-type</b>
New term	9591/3	Splenic B-cell lymphoma/leukaemia with <b>prominent nucleoli</b>
New term	9596/3	<b>Mediastinal grey zone</b> lymphoma
New term	9650/3	<b>Classic</b> Hodgkin lymphoma
New behavior code and term	9673/1	<b>In situ</b> mantle cell neoplasia

Status	ICD-O-3	Term
New term	9673/3	<b>Conventional</b> mantle cell lymphoma <b>Leukaemic non-nodal</b> mantle cell lymphoma <b>Cyclin D1-positive</b> mantle cell lymphoma <b>Cyclin D1-negative</b> mantle cell lymphoma
New term	9678/3	<b>Fibrin-associated large B-cell</b> lymphoma <b>Fluid overload-associated large B-cell</b> lymphoma <b>Extracavitary</b> primary effusion lymphoma
New behavior code and term	9680/1	EBV-positive mucocutaneous ulcer
New term	9680/3	Diffuse large B-cell lymphoma (DLBCL), <b>Germinal centre B-cell subtype</b> Diffuse large B-cell lymphoma (DLBCL), <b>Activated B-cell subtype</b> <b>Fibrin-associated</b> diffuse large B-cell lymphoma <b>High-grade</b> B-cell lymphoma <b>with MYC and BCL2 and/or BCL6 rearrangements</b> <b>High-grade</b> B-cell lymphoma, NOS <b>Vitreoretinal</b> lymphoma (C69.2) <b>Primary large B-cell lymphoma of immune-privileged sites</b> <b>Primary large B-cell lymphoma of the testis</b>
New term	9687/3	<b>High-grade B-cell Burkitt-like</b> lymphoma <b>with 11q aberration</b> <b>Acute leukaemia</b> , Burkitt type <b>Endemic</b> Burkitt lymphoma <b>Sporadic</b> Burkitt lymphoma <b>Immunodeficiency-associated</b> Burkitt lymphoma <b>EBV-associated</b> Burkitt lymphoma <b>EBV-negative</b> Burkitt lymphoma
New term	9690/3	<b>Testicular</b> follicular lymphoma <b>Paediatric-type</b> follicular lymphoma
New behavior code and term	9695/1	<b>In situ</b> follicular neoplasia <b>In situ follicular B-cell</b> neoplasia
New term	9695/3	<b>Duodenal-type</b> follicular lymphoma
New term	9698/3	<b>Large B-cell lymphoma with IRF4 rearrangement</b> <b>Follicular large B-cell</b> lymphoma
New term	9699/3	<b>Primary choroidal</b> lymphoma (C69.3) <b>Primary cutaneous</b> marginal zone lymphoma <b>Primary cutaneous</b> marginal zone lymphoma, <b>heavy chain class-switched form (IgG+, IgA+, or IgE+)</b> <b>Primary cutaneous</b> marginal zone lymphoma, <b>non-class-switched form (IgM+)</b> <b>Paediatric</b> nodal marginal zone lymphoma

Status	ICD-O-3	Term
New term	9700/3	<b>Hypopigmented</b> mycosis fungoides <b>Adnexotropic (folliculotropic and/or syringotropic)</b> mycosis fungoides Pagetoid reticulosis ( <b>Woringer-Kolopp type</b> ) <b>Granulomatous slack skin disease</b>
New behavior code and term	9702/1	<b>Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract</b> <b>Indolent T-cell lymphoma of the gastrointestinal tract</b> <b>Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract</b>
New term	9702/3	<b>Follicular</b> T-cell lymphoma <b>Nodal</b> peripheral T-cell lymphoma <b>with T follicular helper phenotype</b> <b>Nodal T follicular helper cell lymphoma, follicular type</b> <b>Nodal T follicular helper cell lymphoma, NOS</b> <b>EBV-positive nodal T- and NK-cell lymphoma</b>
<b>New term</b>	<b>9705/3</b>	<b>Nodal T follicular helper cell lymphoma, angioimmunoblastic type (ICD-O-4 97028/3)</b>
Behavior code change (3→1)	9709/1	Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder
New term	9709/3	Primary cutaneous <b>acral</b> CD8-positive T-cell lymphoma <b>Primary cutaneous acral CD8 positive T-cell lymphoproliferative disorder</b> <b>Primary cutaneous peripheral T-cell lymphoma, NOS</b>
New term	9714/3	Anaplastic large cell lymphoma, ALK-positive (ALK+ ALCL) <b>Common</b> ALK+ ALCL <b>Small cell</b> ALK+ ALCL <b>Lymphohistiocytic</b> ALK+ ALCL <b>Hodgkin-like</b> ALK+ ALCL <b>Composite</b> ALK+ ALCL
New code and term	<b>9715/3</b>	<b>Anaplastic large cell lymphoma, ALK-negative [originally 9702/3]</b> <b>Breast implant-associated anaplastic large cell lymphoma</b>
New term	9717/3	<b>Monomorphic epitheliotropic</b> intestinal T-cell lymphoma
Behavior code not change	9718/3	Primary cutaneous anaplastic large cell lymphoma
Behavior code change (3→1)	9718/1	Lymphomatoid papulosis (C44._) Lymphomatoid papulosis <b>type A / type B / type C / type D / type E / with DUSP22 locus rearrangement</b> Primary <b>mucosal</b> CD30-positive T-cell lymphoproliferative disorder
New term	9724/3	Systemic EBV-positive T-cell <b>lymphoma</b> of childhood

Status	ICD-O-3	Term
Behavior code change (3→1)	9725/1	Hydroa vacciniforme-like lymphoproliferative disorder Classic hydroa vacciniforme lymphoproliferative disorder Systemic hydroa vacciniforme lymphoproliferative disorder <b>Systemic chronic active EBV-positive disease</b>
New behavior code and term	9727/1	<b>Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm</b>
New term	9732/3	<b>Smouldering (asymptomatic) myeloma</b> <b>Non-secretory myeloma</b>
New behavior code and term	9738/1	HHV8-positive <b>germinotropic lymphoproliferative disorder</b>
New term	9738/3	<b>KSHV/HHV8-positive diffuse</b> large B-cell lymphoma
New code and term	<b>9749/3</b>	<b>Erdheim-Chester disease</b> <b>Rosai-Dorfman disease</b>
New term	9750/3	<b>Alk-positive</b> histiocytosis
Behavior code change (3→1)	9751/1	Langerhans cell histiocytosis, NOS Langerhans cell histiocytosis, monostotic Langerhans cell histiocytosis, polystotic
New term	9758/3	<b>EBV-positive inflammatory</b> follicular dendritic cell sarcoma
New behavior code and term	9760/1	<b>IgG4-related disease</b>
New behavior code and term	9761/1	<b>IgM monoclonal gammopathy of undetermined significance</b>
New term	9761/3	<b>IgM-type lymphoplasmacytic lymphoma</b> / Waldenström macroglobulinaemia <b>Non-IgM-type lymphoplasmacytic lymphoma</b> / Waldenström macroglobulinaemia
New term	9762/3	Heavy chain <b>deposition</b> disease
New term	9765/1	<b>Non-IgM</b> monoclonal gammopathy of undetermined significance
New term	9766/1	Lymphomatoid granulomatosis, <b>grade 1, 2</b>
New behavior code and term	9766/3	<b>Lymphomatoid granulomatosis, grade 3</b>
New term	9769/1	Light chain and <b>heavy chain</b> deposition diseases <b>Monoclonal</b> immunoglobulin deposition diseases
New term	9805/3	Acute leukaemia of <b>ambiguous</b> lineage with <b>other defined genetic alterations</b> <b>Mixed-phenotype</b> acute leukaemia with <b>ZNF384</b> rearrangement Acute leukaemia of <b>ambiguous</b> lineage with <b>BCL11B</b> rearrangement <b>Mixed-phenotype</b> acute leukaemia, <b>B/T (MPAL-B/T)</b> <b>Mixed-phenotype</b> acute leukaemia, <b>B/T/Myeloid (MPAL-B/T/M)</b> <b>Mixed-phenotype</b> acute leukaemia, <b>T/Megakaryocytic (MPAL-T/Mk)</b> Acute leukaemia of <b>ambiguous</b> lineage, <b>NOS</b>

Status	ICD-O-3	Term
New term	9807/3	Mixed-phenotype acute leukaemia with t(v; 11q23.3); <b>KMT2A</b> -rearranged
New term	9811/3	B-lymphoblastic leukaemia/lymphoma <b>with iAMP21</b> B-ALL with <b>DUX4 rearrangement</b> B-ALL with <b>MEF2D rearrangement</b> B-ALL with <b>ZNF384 rearrangement</b> B-ALL with <b>PAX5 alteration</b> B-ALL with <b>PAX5 p.P80R variant</b> B-ALL with <b>NUTM1 rearrangement</b> B-lymphoblastic Leukaemia/lymphoma with <b>other defined genetic alterations</b> B-ALL with <b>MYC rearrangement</b>
New term	9813/3	B-lymphoblastic leukaemia/lymphoma with t(v; 11q23.3); <b>KMT2A</b> -rearranged
New term	9815/3	B-ALL with <b>high hyperdiploidy</b>
New term	9816/3	B-ALL with <b>near-haploidy</b> B-ALL with <b>low hypodiploidy</b> B-ALL with <b>high hypodiploidy</b> B-ALL with <b>hypodiploidy, near-haploidy</b> B-ALL with <b>hypodiploidy, low hypodiploidy</b> B-ALL with <b>hypodiploidy, high hypodiploidy</b>
New term	9818/3	B-ALL with <b>TCF3::HLF fusion</b> B-lymphoblastic leukaemia/lymphoma with TCF3:: <b>PBX1 fusion</b>
New code and term	<b>9819/3</b>	<b>B-lymphoblastic leukaemia/lymphoma, BCR-ABL1-like</b>
New behavior code and term	<b>9823/1</b>	<b>Monoclonal B-cell lymphocytosis, CLL-type</b>
New term	9827/3	<b>Smouldering</b> adult T-cell Leukaemia/lymphoma <b>Chronic</b> adult T-cell Leukaemia/lymphoma <b>Lymphoma</b> adult T-cell Leukaemia/lymphoma <b>Acute</b> adult T-cell Leukaemia/lymphoma
New term	9835/3	<b>NK</b> -lymphoblastic leukaemia/lymphoma
New term	9840/3	<b>Pure</b> erythroid leukaemia
New term	9861/3	AML with <b>NUP98 rearrangement</b> AML with <b>MNX1::ETV6 fusion</b> AML with <b>KAT6A::CREBBP fusion</b> AML with <b>CBFA2T3::GLIS2 fusion</b> Acute myeloid leukaemia <b>with other defined genetic alterations</b> AML with <b>FUS::ERG fusion</b> AML with <b>NPM1::MLF1 fusion</b>

Status	ICD-O-3	Term
New term	9866/3	Acute promyelocytic leukaemia <b>with a variant RARA translocation</b>
New term	9869/3	AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <b>GATA2, MECOM</b> AML with <b>MECOM rearrangement</b>
New term	9876/3	<b>Myelodysplastic/myeloproliferative neoplasm with neutrophilia</b>
New code and term	<b>9877/3</b>	<b>AML with mutated NPM1 [originally 9861/3]</b>
New code and term	<b>9878/3</b>	<b>AML with biallelic mutation of CEBPA [originally 9861/3]</b> <b>Acute myeloid leukaemia with CEBPA mutation [originally 9861/3]</b>
New code and term	<b>9879/3</b>	<b>AML with mutated RUNX1</b>
New term	9897/3	AML with t(9;11)(p21.3;q23.3); <b>KMT2A-MLLT3</b> AML with t(9;11)(p22;q23); <b>KMT2A-MLLT3</b> AML with <b>KMT2A rearrangement</b>
New term	9911/3	Acute myeloid leukaemia with <b>RBM15::MRTFA fusion</b>
New code and term	<b>9912/3</b>	<b>AML with BCR-ABL1</b>
New term	9920/3	<b>Myeloid neoplasm post cytotoxic therapy</b> <b>Myelodysplastic/myeloproliferative neoplasm post cytotoxic therapy</b> Acute myeloid leukaemia <b>post cytotoxic therapy</b>
New term	9945/3	<b>Myelodysplastic chronic myelomonocytic leukaemia (MD-CMML)</b> <b>Myeloproliferative chronic myelomonocytic leukaemia (MP-CMML)</b>
New term	9946/3	Juvenile myelomonocytic leukaemia (JMML) <b>PTPN11-mutated JMML</b> <b>NRAS-mutated JMML</b> <b>KRAS-mutated JMML</b> <b>JMML in neurofibromatosis type 1 (NF1)</b> <b>JMML in children with CBL syndrome</b> <b>JMML-like disorders in children with Noonan syndrome (NS)</b>
New term	9966/3	Myeloid/ <b>lymphoid</b> neoplasms with PDGFRB
New code and term	<b>9968/3</b>	<b>Myeloid/lymphoid neoplasms with PCM1-JAK2</b> <b>Myeloid/lymphoid neoplasms with JAK2 rearrangement</b> <b>Myeloid/lymphoid neoplasm with FLT3 rearrangement</b> <b>Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion</b> <b>Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes</b>
Behavior code change (3→1)	9971/1	Polymorphic PTLD

Status	ICD-O-3	Term
New term	9980/3	<b>Myelodysplastic syndrome with single lineage dysplasia</b> <b>Myelodysplastic neoplasm with low blasts and single-lineage dysplasia</b>
New term	9982/3	<b>Myelodysplastic/myeloproliferative neoplasm with ring siderolasts and thrombocytosis</b> <b>Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia</b> <b>Myelodysplastic neoplasm with low blasts and SF3B1 mutation</b> <b>Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis</b>
New term	9983/3	<b>Myelodysplastic syndrome with excess blasts</b> <b>Myelodysplastic neoplasm with increased blasts/blasts-1/blasts-2/blasts and fibrosis</b> <b>Childhood myelodysplastic neoplasm with increased blasts</b>
New term	9985/3	<b>Myelodysplastic syndrome with multilineage dysplasia</b> <b>Myelodysplastic neoplasm with biallelic TP53 inactivation</b> <b>Myelodysplastic neoplasm with low blasts</b> <b>Myelodysplastic neoplasm with low blasts and multilineage dysplasia</b> <b>Myelodysplastic neoplasm, hypoplastic</b> <b>Childhood myelodysplastic neoplasm with low blast</b> <b>Childhood myelodysplastic neoplasm with low blast, hypocellular</b>
New term	9986/3	<b>Myelodysplastic neoplasm with low blasts and 5q deletion</b>
New code and term	<b>9993/3</b>	<b>Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia</b>

說明：綠色網底表示為本次新增編碼或增修敘述。